AMS was an agricultural products company founded in the 1980s. When new owners purchased the company in 2011, they wanted to create a new brand that would support multiple products.

Strategy + Tactics. Messaginglab defined the company’s positioning, created new messages, then invented a new name – AGRICEN. We also wrote a series of cornerstone content pieces that contributed to the company’s digital marketing efforts.

Results. The company experienced increased website traffic and social media engagement.

Eventually, Agricen was acquired by one of the world’s leading agricultural products and services providers.

Asimov develops software to create biological circuits. The company’s technology can help biotechnology companies better manufacture a product and create novel, biological tools.

Strategy + Tactics. Messaginglab used Asimov's funding announcement to start a conversation about biocircuit design and its potential.

We defined launch messages, wrote the media release, and helped craft corporate and funder blog posts. We also conducted media training and identified and pre-pitched reporters. On launch day, we conducted media outreach.

Results. The launch generated media coverage in BioFuels Digest, BostonInno, Boston Biz Journal, Fortune, Healthcare Analytics News, Industrial Biotech, TechCrunch and TechCrunch Japan, Techstartups, SynBioBeta, WBZ (radio), Wired, and Xconomy. In addition, the launch also resulted in inquiries from ten venture firms and five potential clients.

Biomatter optimizes existing enzymes and engineers de novo enzymes with unique functions for industrial applications. The Biomatter team sought to amplify their presence and meet key stakeholders at the annual SynBioBeta conference. To achieve this, they partnered with Messaginglab to optimize their conference strategy and clarify their messaging.

Strategies + Tactics. Messaginglab collaborated with Biomatter to tailor an approach based on its Go-to-Conference strategy. We identified key industry influencers and crafted compelling LinkedIn content to drive engagement and generate high-quality leads. Additionally, we developed a targeted advertisement for the SynBioBeta digest to maximize visibility and reach. To ensure a powerful on-stage presence, MessagingLab provided comprehensive coaching to Biomatter’s VP of Programs for their Lightning Talk.

Results. With Messaginglab’s strategic guidance, Biomatter successfully connected with key clients and solidified its position as a leading enzyme development company. By effectively communicating their groundbreaking technology and scientific expertise, Biomatter enhanced its brand visibility and generated substantial interest in its innovative solutions. Remarked Laurynas Karpus, “ Working with ML gave us a fresh perspective on our communication and positioning strategy and allowed us to communicate our technology more consistently and clearly to clients. At SynBioBeta, we connected with key industry players thanks to Messaginglab’s extensive network. Messaginglab helped us showcase what makes us unique, giving us the confidence to present our company more boldly.”

Bota Bio is a US/Chinese integrated bio-manufacturing platform that provides organism engineering services to companies in the materials, nutrition, and agricultural spaces. This Chinese-based biotech startup is a small, pioneering company looking to move from under the radar to make headlines.

Strategy + Tactics. The company had just raised $100 million in series B funding and wanted to tell the world about this funding. To attract high-level talent and get Bota Bio on the map, Messaginglab developed the messaging for the announcement. We aided in improving clarity around their messaging, including minor refinements to their website. We drafted the press release and provided media training for the CEO and an additional team member.

Results. Bota Bio's Series B announcement received original coverage by Reuters, Forbes, BioCentury, Endpoints, C&EN, BioSpace, Drug Discovery Trends, Crunchbase, VC News Daily, VC Journal, and Law360. On the day of the release, 147 outlets posted our release for a total estimated audience reach of 130.7 million. In addition, the information went viral on Twitter, gaining an even wider spread.

A C-suite executive at a clinical research organization wanted to increase his influence among internal and external professional audiences. The challenge was finding the appropriate channels to communicate, developing story topics to engage multiple audiences, and positioning the executive as an expert.

Strategy + Tactics. Messaginglab developed a thought leadership strategy that included content creation. We wrote and published content on LinkedIn and created regular updates on LinkedIn.

Results. A 10-fold increase in LinkedIn connections, engagement from internal audiences, and multiple invitations to speak at industry events.

When Cegedim launched its physician-only social network, DocNet, it entered a crowded marketplace. The company needed to communicate to physicians the value of joining this new network.

Strategy + Tactics. Messaginglab created a content strategy based on the Hero’s Journey, a category of stories that involve a hero who goes on an adventure, is tested by a crisis, and comes home transformed.

The plan leveraged existing social networks to engage physicians with content wherever they might be on their “hero’s journey.”

Results. Upon executing the plan, DocNet saw month-over-month double-digit membership growth.

Core Biogenesis is a biomanufacturing company that uses plants to scale the production of recombinant proteins. Their Ultra-scalable bioproduction as a service platform accelerates mass production and increases yields while driving down costs.

After receiving its seed round of funding, Core Biogenesis wanted to refine its message and website to recruit talent and be ready for its Series A funding later that year.

Strategy + Tactics. Messaginglab developed a communications roadmap for Core Biogenesis. We did a story workshop to work with the brand to develop and refine messages. We worked with Transfuture to develop an updated website to provide this messaging and information about bio geneticists and their technology. We also drafted a foundational blog post the company has been using for sales and business development efforts.

Results. Core Biogenesis expressed their appreciation for the great work delivered in time. As a result, they have increased their staff size and have received inquiries into their business. Their message for biotech founders: "Messaginglab is your partner of choice to craft and hone your messaging strategy."

Degron Therapeutics is a biotechnology company advancing human health by developing a new class of targeted protein degradation medicines, using its molecular degradation drug discovery platform. As a new company founded in 2021, Degron Therapeutics came to Messaginglab seeking more visibility in the growing molecular glue industry. 

Strategy + Tactics. Ahead of the BIO International Convention in June 2022, Messaginglab helped Degron Therapeutics refine their messages, define their target audience, and co-wrote and distributed a $22 million Series A financing announcement press release. Messaginglab also conducted phone and email outreach to reporters and delivered media reports to track coverage of the release.

Results. The funding announcement gained coverage from 377 total media outlets, including BioSpace, Endpoints News, BioWorld, Scrip, and Chemical and Engineering News, garnering over 6,000 views and putting Degron Therapeutics on the map in the molecular glue development space. Following the success of the funding release, Degron Therapeutics announced IND-enabling studies of its novel molecular glue preclinical candidate that degrades a previously “undruggable” RNA binding protein with indications in multiple solid tumors.

Epigene Labs is creating intelligence-augmenting data science solutions for precision oncology research and drug development. The company's mCUBE platform accelerates data-driven drug discovery, biomarker identification, and patient selection to bring better treatments to patients faster. A seed-stage company that spun out of Harvard Innovation Labs, Epigene Labs needed clear messaging.

Strategy + Tactics. Messaginglab worked with Epigene Labs to create a communications roadmap and recommended creating an audience system that included messages for investors, media, and the internal team. We also drafted foundational content and FAQs and delivered a media relations strategy around key news events. Messaginglab edited and offered counsel on Epigene Lab’s fundraising messages and deck.

Results. Epigene Labs’ messaging differentiates the company from other AI-driven drug discovery companies. Messaginglab trained Epigene Labs’ internal team on company storytelling, co-authored the company foundational blog post with CEO Akpéli Norder, helped create internal and external FAQs, and continues to offer communications counsel to the leadership team.

K18 is a biotechnology company that creates and markets hair care products. The company had started to market to consumers but wanted to increase the amount of science and biotech included in their consumer messaging.

As the future of consumer biotechnology, K18 came to messagingLAB to make the science behind their products accessible to customers.

Strategy + Tactics. Messaginglab has become a part of the core team at K18. We have researched the science behind the product. Messaginglab has told the story behind the science by providing several science-based pieces around hair damage, strength, elasticity, and others. In addition, Messaginglab provided thought leadership messaging for the CEO and suggested biotech conferences to attend.

Results. As a result of Messaginglab’s work, K18 has published well-received science-based blogs about their products. Their Instagram and TikTok content also includes this science content, saturating the market with the biotech and science stories that power the K18 brand.

Medikly, a marketing automation platform designed to help brands engage physicians, was challenged to meet its marketing and sales goals.

Strategy+ Tactics. Messaginglab developed investment, sales, and media strategies to attract investors, engage brands, and drive media coverage. The story was adapted for investors, customer acquisition, and media since each has its preferred way of receiving a story. For investors, the story was told in person; for customers, over the phone, then in person; for media, on the phone.

Results. A $1.5 million Series A financing from a leading healthcare venture capital firm, more than $2 million in year-one revenues, and media coverage in Contract Pharma, FierceHealthIT, GigaOm, MedCityNews, and TechCrunch, among others.

For Novartis Vaccines & Diagnostics, Messaginglab served as internal communications counsel during the divestiture of the business to GlaxoSmithKline. The challenge was to inspire employees and keep them focused on producing excellence during a year-long emotional transition.

Strategy + Tactics. Messaginglab developed content that highlighted the company’s scientific discoveries and profiled corporate leaders dedicated to continuing to do their best work while awaiting the outcome of the divestiture.

We also wrote an internal blog for the Chief Scientific Officer, one of the world’s leading vaccinologists.

Results. Our content was considered the most engaging and widely read on Novartis’ internal website based on traffic and comments.

Officinae Bio, a pioneer in DNA and RNA synthesis for cell and gene therapy development, sought to optimize its conference strategy ahead of the critical BIO-Europe event. Partnering with Messaginglab just four weeks before the conference, Officinae aimed to identify and engage with key decision-makers in the cell, gene and mRNA therapy spaces.

Strategy + Tactics. Messaginglab crafted a tailored approach based on its Go-To-Conference strategy, which identifies high-value prospects, prioritizes sessions to attend, and crafts compelling content pre- and post-evetn. Through scenario-based training and follow-up counsel, the Officinae team was empowered to engage potential partners at and after the conference confidently. 

Results. Armed with Messaginglab's insights and strategic guidance, Officinae CEO Davide De Lucrezia expressed increased confidence and preparedness for BIO-Europe. Moreover, a strategic introduction facilitated by Messaginglab culminated in a significant mid-five figures deal. When asked whether the Go-To-Conference strategy worked, Davide De Lucrezia, Ph.D. said, “I had never attended a conference so well prepared. Thanks to a meeting you helped arrange, we closed a mid-five figures deal just after that conference.”

PAREXEL provides multiple clinical development services, and must constantly educate buyers on its offerings.

Strategy + Tactics. For more than five years, Messaginglab has supported this clinical research leader with marketing and content strategy. We write articles, brochures, datasheets, and white papers. These have covered topics as diverse as cancer immunotherapy, clinical trial supply chain, CNS drug development, data management, direct-to-patient trials, and global regulatory changes.

Results. Messaginglab’s marketing strategies and content have been essential for several multi-million dollar campaigns.

Tom Baruch invests in innovative early-stage businesses with a focus on synthetic biology, clean water, renewable energy, and smart grid solutions through Baruch Future Ventures. A pioneer in corporate venture capital, Baruch was one of the earliest investors to see the potential returns in applying biotechnology to real-world challenges. Baruch came to Messaginglab to refine his messaging and bring his thought leadership ideas to life.

Strategy + Tactics. Messaginglab worked with Baruch to generate a thought leadership strategy that included key messages, thought-leadership content, and publication.

Results. Messaginglab defined key messages that highlighted the driving force behind Baruch Future Ventures’ investment thesis, then created a series of thought leadership-focused articles for Baruch. The content, which was published on Greenbiz.com, covered a myriad of subjects including the intersection between energy, sustainability, and biotechnology and the importance of entrepreneurship in the face of climate change.

Messaginglab also helped Baruch draft “The Synthetic Biology Climate Change Opportunity,” a piece that explains the steps necessary for entrepreneurs to build a billion-dollar business in ten years. For more information on Tom Baruch, read Messaginglab’s exclusive interview on our blog.

Transparency Life Sciences is a virtual drug development organization that uses digital tools to design and execute clinical studies. TLS engaged Messaginglab to serve as their virtual strategy and marketing team upon receiving their series A funding.

Strategy + Tactics. After holding a series of strategy and content workshops, Messaginglab developed strategies for marketing and communications that included conference attendance, content marketing, and social media.

Results. Initial results have included coverage in the Medicine Maker, invitations to speak at several trade shows, and a growing number of leads.

World Courier is a specialty logistics company that serves global clinical biopharmaceutical trials. The company needed to generate prospects for its new cell and gene therapy (CGT) logistics service.

Strategy + Tactics. Messaginglab created a 12-week content-driven campaign to promote a white paper to attract potential buyers. Channel-specific content drove leads to a landing page on WorldCourier.com and offered a download or a multi-step email course.

Content was created for LinkedIn, Facebook, Instagram, and Twitter. Our strategy also included recommendations on inclusion in newsletters and paid media.

Results. The campaign generated 100,000 website sessions and 321 downloads. Of those downloads, 20 percent scored A- and above. Twenty-four of the CGT ebook downloads came from the top 60 cell and gene therapy companies.